Myall Nathaniel J, Das Millie
Division of Oncology, Department of Medicine, Stanford Cancer Center, Stanford CA, United States.
Division of Oncology, Department of Medicine, Stanford Cancer Center, Stanford CA, United States; Department of Medicine, VA Palo Alto Health Care System, 3801 Miranda Ave. (111ONC), Palo Alto CA 94304, United States.
Curr Probl Cancer. 2024 Dec;53:101133. doi: 10.1016/j.currproblcancer.2024.101133. Epub 2024 Sep 10.
Rearrangements involving the ROS1 gene are infrequent in non-small cell lung cancer (NSCLC) but represent an important targetable driver alteration. Occurring most commonly in patients with adenocarcinoma who have a light or never smoking history, ROS1 rearrangements can be identified by either fluorescence in-situ hybridization (FISH) or next-generation sequencing techniques. Multiple tyrosine kinase inhibitors (TKIs) are now available for the effective treatment of ROS1-rearranged NSCLC in the metastatic setting including crizotinib, entrectinib, and repotrectinib as first-line therapy options. In addition, newer targeted therapies with increased selectivity for ROS1 over other targets are also emerging. As treatment of the disease continues to evolve, understanding the clinical course of patients with ROS1-rearranged NSCLC as well as the data supporting the latest therapy options is key to timely, effective, and longitudinal care.
涉及ROS1基因的重排在非小细胞肺癌（NSCLC）中并不常见，但却是一种重要的可靶向驱动改变。ROS1重排最常发生于腺癌且有轻度吸烟史或从不吸烟的患者中，可通过荧光原位杂交（FISH）或下一代测序技术来识别。目前有多种酪氨酸激酶抑制剂（TKIs）可有效治疗转移性ROS1重排的NSCLC，包括克唑替尼、恩曲替尼和瑞波替尼作为一线治疗选择。此外，对ROS1比对其他靶点具有更高选择性的新型靶向疗法也在不断涌现。随着该疾病治疗的不断发展，了解ROS1重排NSCLC患者的临床病程以及支持最新治疗选择的数据是实现及时、有效和长期护理的关键。
